Comparison of Vaginal Versus Sublingual Misoprostol in the Treatment of First Trimester Missed Miscarriage

Sponsor
Islamabad Medical and Dental College (Other)
Overall Status
Completed
CT.gov ID
NCT04604366
Collaborator
(none)
120
1
2
13.9
8.6

Study Details

Study Description

Brief Summary

The miscarriage is one of the adverse outcomes of pregnancy and is responsible for stress and anxiety of the couple. there are different types of miscarriages.missed miscarriage also known as early fetal demise is one of the type of miscarriage in which patient is mostly asymptomatic but Ultrasound shows absent fetal cardiac activity.Traditionally surgical evacuation of uterus was the treatment of choice for miscarriage.The treatment of miscarriage has evolved significantly in recent years.medical management using misoprostol is the newest treatment option.Misoprostol is a synthetic prostaglandin E(1) analogue that is commonly used for medical miscarriage It can be given orally, vaginally and sublingually.

Condition or Disease Intervention/Treatment Phase
Phase 2

Detailed Description

This study will be conducted in gynae and obstetric department of Akbar Niazi teaching hospital.Patients coming to gynaecology Outpatient department having confirmed diagnosis of missed miscarriage on pelvic ultrasound in first trimester will be enrolled after taking written consent for medical treatment.Patients will be randomly selected for oral or vaginal route of misoprostol,dosage according to international federation of gynaecology and obstetrics protocol.

Vaginal dose---800 microgram 3 hourly two doses Sub lingual 600 microgram 3 hourly two doses Patients will be observed for vaginal bleeding and expulsion for 24 hours if no expulsion or vaginal bleeding occurred then dose will be repeated .maximum of two cycles will be given. Failure of treatment confirmed by Ultrasonography will be dealt with surgical evacuation In case of heavy vaginal bleeding or expulsion pelvic USG will be done to confirm.After admission baseline investigation and coagulation studies will be performed . demographic details will be recorded...

Patients will be assessed for time taken in complete expulsion of conceptus. No of doses required Need for surgical evacuation Haemorrhage Fall in Hb level Need of blod transfusion Patient satisfaction Side effects of misoprostol like shivering,fever diarrhea and oral ulcers and others EXCLUSION CRITERIA patients who opted for surgical management or expectant management. Gestational age >13 weeks Patients with co-morbidity

Sample size: A total of 120 women will be selected for the study, divided into two equal groups of 60 women in each group. The sample size was calculated by WHO sample size calculator with of help of 5% level of significance, 90% power of test, 48% vs. 20% overall complication rate in sub inguinal and vaginal misoprostol groups (???).

Statistical analysis: All the collected data will be entered into SPSS v. 21 for analysis. Quantitative data will be presented in the form of mean ± standard deviation. Independent sample t-test will be applied to compare the quantitative variables (like age and gestational age) between both groups. Frequency with percentages will be calculated for qualitative data and chi-square test will be used to compare the qualitative variables (like abortion and complications) between both groups. P-value ≤ 0.05 will be taken as significant.

Study Design

Study Type:
Interventional
Actual Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Masking Description:
lottery method will be used .one hundred and twenty slips will be made .60 will be marked as group A and 60 will be as Group B. these will be put in basket .and will be picked by the team member
Primary Purpose:
Treatment
Official Title:
Comparison of Vaginal Versus Sublingual Misoprostol in the Treatment of First Trimester Missed Miscarriage
Actual Study Start Date :
Nov 2, 2020
Actual Primary Completion Date :
Dec 15, 2021
Actual Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: vaginal mesoprostol

Vaginal dose---800 microgram 3 hourly two doses

Drug: misoprostol
it stimulates uterine contractions
Other Names:
  • prostaglandin E1
  • Experimental: sublingual mesoprostol

    Sub lingual 600 microgram 3 hourly two doses

    Drug: misoprostol
    it stimulates uterine contractions
    Other Names:
  • prostaglandin E1
  • Outcome Measures

    Primary Outcome Measures

    1. Number of participants with complete expulsion of conceptus. [six months]

      primary outcome measure is to record the number of patients in each group who achieved complete expulsion of products of conception.complete expulsion will be confirmed by pelvic USG

    Secondary Outcome Measures

    1. Number of patients having side effects of misoprostol like shivering, fever diarrhea and oral ulcers and others [six months]

      through physical examination and detailed history

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 40 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Confirmed diagnosis of missed miscarriage on pelvic ultrasound

    • Gestational age ≤ 13 weeks

    Exclusion Criteria:
    • Patients who opted for surgical or expectant management.

    • Patients with co-morbidity

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Islamabad Medical and Dental College Islamabad Federal Pakistan 44000

    Sponsors and Collaborators

    • Islamabad Medical and Dental College

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Afnan Rizwan, Assistant professor, Islamabad Medical and Dental College
    ClinicalTrials.gov Identifier:
    NCT04604366
    Other Study ID Numbers:
    • IslamabadMDC
    First Posted:
    Oct 27, 2020
    Last Update Posted:
    May 24, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Afnan Rizwan, Assistant professor, Islamabad Medical and Dental College
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 24, 2022